دورية أكاديمية
أعرض في EDS

Polypharmacy, Gender Disparities, and Ethnic and Racial Predispositions in Long QT Syndrome: An In-Depth Review.

التفاصيل البيبلوغرافية
العنوان: Polypharmacy, Gender Disparities, and Ethnic and Racial Predispositions in Long QT Syndrome: An In-Depth Review.
المؤلفون: Lima B; Medicine, University of Grande Rio, Rio Grande, USA., Razmjouei S; Anesthesiology, Case Western Reserve University School of Medicine, Cleveland, USA., Bajwa MT; Internal Medicine, Services Hospital Lahore, Lahore, PAK., Shahzad Z; Internal Medicine, Fatima Jinnah Medical University, Lahore, PAK., Shoewu OA; Family Medicine, Hackensack University Medical Center, Hackensack, USA., Ijaz O; Internal Medicine, Services Hospital Lahore, Lahore, PAK., Mange P; Internal Medicine, K.J. Somaiya Hospital and Research Center, Mumbai, IND., Khanal S; Internal Medicine, Lumbini Medical College, Kathmandu, NPL., Gebregiorgis T; General Practice, Addis Ababa University Medical Faculty, Addis Ababa, ETH.
المصدر: Cureus [Cureus] 2023 Sep 26; Vol. 15 (9), pp. e46009. Date of Electronic Publication: 2023 Sep 26 (Print Publication: 2023).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Long QT syndrome (LQTS) is a complex disorder of cardiac electrophysiology. It is characterized by delayed myocardial polarization leading to QT prolongation and alterations on the ST segment and T wave visible on electrocardiogram (ECG). Syncope is a common manifestation, and torsade de pointes (TdP) can lead to sudden cardiac death. Three major LQTS genes (KCI31, KCNH2, and SCN5) lead to most of the cases of LQTS. Lifestyle modifications, beta blockers, and implantable cardioverter defibrillator (ICD) placement are the main treatments for LQTS. Polypharmacy, including QT-prolonging drugs, has been shown to worsen LQTS. The impact on potassium channels and the human ether-a-go-go-related gene (hERG) is the mechanism behind the QT interval prolongation caused by these medications. There is an increased incidence of LQTS among African-American men and women as compared to Caucasians. Women with LQTS tend to have a higher mortality rate from the condition, especially during menstruation and shortly after giving birth. Genetic testing is reserved to those patientswho exhibit either a strong clinical index of suspicion or experience persistent QT prolongation despite their lack of symptoms. Knowing the genetics, racial, and gender discrepancies can help improve patient management and a better comprehension on each case. Proper understanding of how ion channels function and their interaction with medications will lead to a better comprehension and to develop effective forms to treat those patients.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Lima et al.)
References: J Am Heart Assoc. 2015 Feb 23;4(2):. (PMID: 25713294)
J Clin Hypertens (Greenwich). 2006 Jan;8(1 Suppl 1):21-30. (PMID: 16415637)
Circ Arrhythm Electrophysiol. 2013 Aug;6(4):705-11. (PMID: 23728945)
Epilepsy Behav. 2013 Mar;26(3):421-6. (PMID: 23218812)
Curr Probl Cardiol. 2019 Mar;44(3):92-106. (PMID: 29784533)
Am Heart J. 2014 Nov;168(5):749-56. (PMID: 25440804)
Am J Cardiol. 1998 Feb 15;81(4):453-9. (PMID: 9485136)
Am J Med Genet A. 2005 Oct 1;138A(2):107-12. (PMID: 16149070)
Circulation. 1999 Dec 14;100(24):2431-6. (PMID: 10595956)
J Insur Med. 2015;45(2):81-7. (PMID: 27584843)
Chest. 1975 Sep;68(3):369-71. (PMID: 1157544)
Biopharm Drug Dispos. 1997 Aug;18(6):533-41. (PMID: 9267685)
J Am Coll Cardiol. 2000 Jul;36(1):1-12. (PMID: 10898405)
J Am Coll Cardiol. 2004 Feb 18;43(4):565-71. (PMID: 14975464)
Circulation. 2020 Oct 13;142(15):e214-e233. (PMID: 32929996)
J Physiol. 2016 May 1;594(9):2459-68. (PMID: 26660066)
J Electrocardiol. 2014 Mar-Apr;47(2):244-50. (PMID: 24438862)
Pak J Med Sci. 2015 Sep-Oct;31(5):1269-71. (PMID: 26649027)
Am J Cardiol. 2012 Apr 15;109(8):1223-8. (PMID: 22245412)
Heart Rhythm O2. 2021 Jan 22;2(1):89-106. (PMID: 34113909)
Expert Opin Drug Saf. 2020 May;19(5):559-564. (PMID: 32189527)
Am J Emerg Med. 1996 Jan;14(1):95-6. (PMID: 8630169)
J Am Coll Cardiol. 2006 Aug 15;48(4):747-53. (PMID: 16904544)
Front Pharmacol. 2020 May 04;11:550. (PMID: 32431610)
JACC Clin Electrophysiol. 2022 May;8(5):687-706. (PMID: 35589186)
Acta Clin Croat. 2021 Dec;60(4):739-748. (PMID: 35734489)
Front Cardiovasc Med. 2021 Feb 22;8:625449. (PMID: 33693037)
J Clin Endocrinol Metab. 1998 Jun;83(6):2104-9. (PMID: 9626146)
Eur Heart J. 2022 Dec 21;43(48):4976-4977. (PMID: 36254679)
Circulation. 2014 Jul 15;130(3):224-34. (PMID: 24895457)
J Clin Psychiatry. 2001 Mar;62(3):191-8. (PMID: 11305706)
Ann Noninvasive Electrocardiol. 2010 Jan;15(1):73-6. (PMID: 20146785)
Int J Mol Sci. 2023 Jan 10;24(2):. (PMID: 36674868)
Eur Heart J. 2016 May 07;37(18):1456-64. (PMID: 26715165)
J Am Coll Cardiol. 2008 Jun 17;51(24):2291-300. (PMID: 18549912)
Circ Arrhythm Electrophysiol. 2020 Dec;13(12):e008830. (PMID: 33198487)
J Cardiovasc Electrophysiol. 2021 Nov;32(11):3057-3067. (PMID: 34427958)
J Am Coll Cardiol. 2013 Jul 16;62(3):169-180. (PMID: 23684683)
Epidemiology. 2014 Nov;25(6):790-8. (PMID: 25166880)
Psychosomatics. 2018 Mar - Apr;59(2):105-122. (PMID: 29275963)
Psychosomatics. 2013 Jan-Feb;54(1):1-13. (PMID: 23295003)
J Am Coll Cardiol. 2016 Mar 8;67(9):1053-1058. (PMID: 26940925)
Hosp Pediatr. 2020 Apr;10(4):369-375. (PMID: 32144177)
Am Heart J. 2012 Sep;164(3):434-41. (PMID: 22980312)
Drugs. 2002;62(11):1649-71. (PMID: 12109926)
Circulation. 2005 Sep 20;112(12):1701-10. (PMID: 16157773)
J Arrhythm. 2016 Oct;32(5):373-380. (PMID: 27761161)
J Hypertens. 2001 Oct;19(10):1883-91. (PMID: 11593111)
Arch Intern Med. 2011 Oct 24;171(19):1727-33. (PMID: 22025428)
Pacing Clin Electrophysiol. 1997 Aug;20(8 Pt 2):2052-7. (PMID: 9272507)
Can J Cardiol. 2014 Jul;30(7):783-92. (PMID: 24970790)
Can J Psychiatry. 2002 Feb;47(1):27-38. (PMID: 11873706)
J Clin Psychiatry. 2000 Jun;61(6):441-6. (PMID: 10901343)
BMC Geriatr. 2017 Oct 10;17(1):230. (PMID: 29017448)
Curr Clin Pharmacol. 2017;12(4):210-222. (PMID: 29473523)
Arrhythm Electrophysiol Rev. 2018 Aug;7(3):187-192. (PMID: 30416732)
J Am Coll Cardiol. 2012 Nov 13;60(20):2100-2. (PMID: 23083777)
Int J Cardiol. 2004 May;95(1):1-6. (PMID: 15159030)
Can J Cardiol. 1992 Sep;8(7):690-5. (PMID: 1422988)
J Am Heart Assoc. 2016 Mar 25;5(3):e002956. (PMID: 27016575)
Am J Psychiatry. 1997 Jun;154(6):782-91. (PMID: 9167505)
Psychopharmacol Bull. 1998;34(1):61-9. (PMID: 9564200)
Indian Heart J. 2017 Nov - Dec;69(6):707-713. (PMID: 29174246)
Psychopharmacology (Berl). 2023 Jan;240(1):199-202. (PMID: 36515735)
Methodist Debakey Cardiovasc J. 2014 Jan-Mar;10(1):29-33. (PMID: 24932360)
J Clin Invest. 2005 Aug;115(8):2018-24. (PMID: 16075042)
Acta Anaesthesiol Scand. 2014 Mar;58(3):266-72. (PMID: 24397608)
Pediatr Cardiol. 2019 Oct;40(7):1419-1430. (PMID: 31440766)
Psychopharmacology (Berl). 2006 Sep;187(4):415-23. (PMID: 16810505)
Pharmacogenetics. 2000 Dec;10(9):761-6. (PMID: 11221602)
Ann N Y Acad Sci. 2008 Mar;1123:113-8. (PMID: 18375583)
فهرسة مساهمة: Keywords: gender disparity; genetic mechanisms; polypharmacy; racial predisposition; schwartz score
تواريخ الأحداث: Date Created: 20231030 Latest Revision: 20231031
رمز التحديث: 20231031
مُعرف محوري في PubMed: PMC10600617
DOI: 10.7759/cureus.46009
PMID: 37900391
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.46009